Haemonetics Corporation announced the appointment of Christopher Simon as President and Chief Executive Officer of the Company.
Chris, who currently serves as a Senior Partner of McKinsey & Company where he leads the Global Medical Products Practice, will assume his duties on May 16, 2016.
“With over twenty years of experience consulting in the medical device and pharmaceutical industries, Chris has a proven track record of helping businesses transform and grow,” the Haemonetics Board of Directors said in a statement. “Under Chris’ leadership, we are confident that the Company will grow and innovate to serve our customers worldwide.”
Chris will succeed Ronald Gelbman, who had been serving as interim Chief Executive Officer since September of 2015. Gelbman will continue to serve as a member of the Haemonetics Board of Directors.
“Haemonetics has such a well-earned reputation in plasma collection, donor centers and hospitals, and I am honored to have been chosen to lead this Company,” Simon said. “I look forward to advancing the strategic plan developed with the Haemonetics leadership team and Board of Directors to drive Haemonetics towards a bright future.”
Simon has been the Lead Partner for McKinsey & Company’s current strategy review with Haemonetics providing him with insight into the current state of the business as well as the strategies for the future of Haemonetics. He has been with McKinsey & Company since 1993, prior to that, he served in commercial roles with Baxter Healthcare Corporation.
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).